Osaka University Venture Capital

Ayumo is a technology company specializing in AI-driven healthcare solutions. It offers a platform that leverages medical knowledge and AI to assist doctors in diagnoses, suggest examination sequences, and detect locomotive syndrome. The platform also provides users with wellbeing consultations and recovery recommendations, promoting digital transformation in the medical field.

RegCell focuses on developing innovative therapies by modulating or controlling the immune system. Its primary objective is to treat patients with autoimmune diseases and cancer.

QunaSys is a company focused on advancing the practical application of quantum technology through the development of algorithm and application software. Established to harness the potential of quantum physics, QunaSys aims to illuminate the underlying quantum phenomena that influence various technologies, from semiconductors to medical imaging. Their platform enables the simulation of quantum mechanical behaviors, allowing researchers to effectively execute quantum chemistry calculations on both quantum computers and simulators. By bridging the gap between theoretical quantum physics and real-world applications, QunaSys seeks to facilitate innovations that were previously unattainable with conventional technologies, thereby contributing to the evolution of quantum computing and its related fields.

A-Wave is a manufacturing company specializing in medical devices. It develops and markets innovative solutions, including a remote medical treatment system featuring a wristwatch-type wearable device. This device detects cardiac murmurs, reduced activity, and peripheral colds, enabling early symptom detection of heart failure in patients at home.

Alpha Fusion specializes in the production of radiopharmaceuticals based on astatine-211 for targeted alpha therapy, aiming to provide innovative cancer treatment options.

Founded in Japan in 2017, Luxna Biotech specializes in developing nucleic acid drugs using advanced artificial technology. The company focuses on creating safe and effective oligonucleotide therapeutics based on licensed cross-linked modified nucleic acid groups.

Celaid Therapeutics specializes in the development and commercialization of regenerative medicine products. Its platform focuses on creating medicines using human hematopoietic stem cell expansion technology, supporting research for media reagents, and facilitating hematopoietic stem cell transplantation.

Red Arrow Therapeutics is a biotechnology company developing innovative cancer therapies. It focuses on systemic cytokine delivery, targeted intratumoral activation, and enhancing biological potency to maximize drug efficacy while minimizing toxicity.

Restore Vision is a biotechnology company focused on developing innovative therapies for eye diseases, particularly retinitis pigmentosa. The company specializes in gene therapy that employs advanced chimeric rhodopsin genes, which enhance the functionality of conventional rhodopsins. This technology aims to address the limitations of traditional treatments, providing high sensitivity and improved outcomes for patients suffering from intractable eye conditions. Through its research and development efforts, Restore Vision seeks to create effective therapeutic agents that significantly contribute to the field of ocular health.

Thinker provides sales of proximity sensors and proposed solutions using these products.

EX-Fusion is focused on developing and operating the world's first laser-powered commercial nuclear fusion reactor, aiming to provide a sustainable energy solution. The company specializes in the manufacture of continuous plasma generators and is involved in laser-plasma research, offering technology and R&D support for fusion systems. By advancing the practical application of laser fusion, EX-Fusion seeks to overcome the challenges often faced by government-funded fusion research, which can be hindered by shifting political priorities and budget constraints. Through its innovative approach, EX-Fusion aims to contribute significantly to the field of clean energy.

Founded in 2015 as a spin-off from Kyushu University, GAIA BioMedicine is a biopharmaceutical company specializing in regenerative medicine products. It focuses on developing cell therapies and immunotherapies to treat intractable malignancies.

Founded in 2015 as a spin-off from Kyushu University, GAIA BioMedicine is a biopharmaceutical company specializing in regenerative medicine products. It focuses on developing cell therapies and immunotherapies to treat intractable malignancies.

SK Fine specializes in advanced ceramics manufacturing. It pioneered Japan's first commercial 3D printer for ceramics and offers custom 3D ceramic parts based on client-provided CAD data.

JiMED develops a wireless embedded Brain-Computer Interface (BCI) system designed to read brain activity. The company offers an implantable device that uses artificial intelligence to interpret brain signals, enabling individuals with conditions like ALS to enhance communication and improve quality of life.

Immunosens develops electrochemical measurement devices that evaluate biomarkers such as genes, proteins, and cell signals through electrode reactions. Its sensors rely on disposable printable electrodes, enabling healthcare professionals to obtain accurate analyses for medical diagnostics and food safety testing. The platform aims to deliver rapid, on-site biomarker readouts and can be integrated into existing clinical workflows, offering a scalable solution for both clinical and food industry applications.

HULIX Technologies specializes in the development and sale of human flow space analysis platforms that facilitate the understanding of human behavior and spatial dynamics. The company's offerings include Human Navigation Research, which automatically gathers and visualizes data on human behavior to identify underlying issues, and the Hitonavi Cloud suite, which supports people flow surveys and verifications. Hitonavi Cloud Advanced utilizes collected data to enhance applications in various sectors, including marketing, smart cities, security, and energy management. Additionally, HULIX's digital twin platform aims to bridge the gap between the physical and digital worlds, enabling both humans and AI to navigate real-world environments effectively. By focusing on creating a human-centered environment, HULIX Technologies addresses social challenges and promotes the smart development of modern society and industry.

Founded in 2018, Aipore specializes in developing nanopore sensors using semiconductor Si microfabrication technology. These sensors measure and analyze changes in ion current flow, enabling accurate identification of particles such as viruses for diverse industrial applications like microbiological testing, cancer detection, and environmental evaluation.

COTOBADESIGN, Inc. specializes in the development and delivery of dialogue artificial intelligence (AI) content. Established in 2017 and headquartered in Tokyo, Japan, the company offers innovative tools aimed at enhancing productivity in various sectors, including elderly and nursing care, business automation, and entertainment. Additionally, COTOBADESIGN provides a platform that supports the development of dialogue AI content, catering to the growing demand for automated communication solutions across different markets.

Periotherapia is a drug discovery company focused on developing medical treatments for intractable diseases, with a primary emphasis on triple-negative breast cancer. The company aims to selectively inhibit specific pathways involved in disease progression without affecting physiological processes associated with chronic conditions such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. By utilizing disease-specific antibodies, Periotherapia contributes to early diagnosis and precision medicine, enhancing the ability of healthcare professionals to identify and create new therapeutic options for various challenging medical conditions.

GlyTech specializes in the production of human-type N-glycans and chemical glycosylation technologies. It offers custom synthesis services, contract manufacturing, and licenses its products for use in biopharmaceuticals and oligonucleotide therapeutics.

J-Pharma specializes in developing novel pharmaceuticals based on a human-genomic approach. Its intellectual property focuses on cell membrane transporters linked to various diseases, enabling the creation of targeted drugs and diagnostic methods. The company aims to improve global health and enhance quality of life for aging populations by generating new drug agents.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

ThinkCyte, Inc. is a biotechnology company that specializes in developing an artificial intelligence-enabled, image-free visual cell sorting system, which sorts cells based on their morphology. Founded in 2016 and headquartered in Tokyo, Japan, with an additional office in San Carlos, California, ThinkCyte utilizes advanced optics and machine learning to create its ghost cytometry technology. This innovative approach allows for ultra-high throughput and content-rich analysis of single cells, facilitating research, diagnostics, and therapeutics across various medical disciplines such as drug discovery and cell therapy. The company's cell sorting technology enables researchers to identify and isolate specific cells, including rare ones, in real-time, advancing the capabilities of single-cell analysis.

Kringle Pharma is a Japanese biopharmaceutical company focused on the research and development of hepatocyte growth factor (HGF)–based protein medicines and NK4 therapies. The company aims to leverage HGF’s regenerative properties and NK4’s antiangiogenic activity to address organ repair and cancer indications. Its pipeline includes recombinant human HGF for acute renal failure, spinal cord injury, and CNS diseases, as well as recombinant NK4 and NK4 gene therapies for cancer. Founded in 2001, the company operates in the Japanese market.

Founded in Japan in 2017, Luxna Biotech specializes in developing nucleic acid drugs using advanced artificial technology. The company focuses on creating safe and effective oligonucleotide therapeutics based on licensed cross-linked modified nucleic acid groups.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

Founded in Japan in 2017, Remohab specializes in remote telemedicine solutions for rehabilitation patients. Its core product, the Remohub system, leverages IoT and ICT technologies to connect patients at home with medical institutions remotely, facilitating cardiac rehabilitation.

mediVR specializes in the development and sale of a therapeutic medical device that employs virtual reality, three-dimensional tracking, and artificial intelligence technologies. Its flagship product, mediVR Kagura, is a self-exercise device designed to evaluate and improve motor function, posture balance, and cognitive function required for walking. The company markets its device through distributors.

Immunosens develops electrochemical measurement devices that evaluate biomarkers such as genes, proteins, and cell signals through electrode reactions. Its sensors rely on disposable printable electrodes, enabling healthcare professionals to obtain accurate analyses for medical diagnostics and food safety testing. The platform aims to deliver rapid, on-site biomarker readouts and can be integrated into existing clinical workflows, offering a scalable solution for both clinical and food industry applications.

Cykinso, Inc., founded in 2014 and based in Kawasaki-Shi, Japan, specializes in developing and selling direct-to-consumer microbiome testing kits. The company offers a home-testing solution that assesses the state of an individual's intestinal bacteria. Utilizing advanced sequencing technology, Cykinso's kit rapidly analyzes a vast number of DNA sequences to provide users with insights into their gut health. This information helps individuals understand the relationship between their intestinal flora and various lifestyle-related and digestive diseases, enabling them to make informed health decisions based on their gut microbiome data.

Founded in 2016, MiCAN Technologies specializes in producing and supplying homogeneous blood cells using regenerative medicine technology. These cells facilitate drug safety evaluation, functional material research, and infectious disease studies, with a focus on malaria.

AI Samurai Inc. is a Tokyo-based company founded in 2015 that focuses on the development and sale of artificial intelligence technology. The company specializes in creating a patent examination platform that utilizes AI to evaluate patentability and conduct comprehensive patent searches. This platform supports clients in analyzing patent documents, thereby facilitating research and development efforts. In addition to its core offerings, AI Samurai also engages in patent research and technical investigation, providing valuable insights and services to enhance innovation in the field of artificial intelligence. The company also maintains a branch office in Osaka, expanding its reach within Japan.

Telenoid Healthcare Company Ltd. is a Tokyo-based firm founded in 2015, specializing in innovative solutions for elderly individuals with dementia. The company has developed Terenoid, an app designed to enhance communication between dementia patients and their caregivers through a remote-controlled device equipped with a camera and microphone. Additionally, Telenoid offers the Chatter Box, a consulting service that provides nursing care leaders with a knowledge database to facilitate conversations and improve care practices. This service aids junior staff by allowing them to input and access personality data about seniors, thus fostering a better understanding of their perspectives. Telenoid’s commitment to enhancing the quality of care for the elderly is reflected in its multifaceted approach, which includes applications for research and training in nursing homes.

Periotherapia is a drug discovery company focused on developing medical treatments for intractable diseases, with a primary emphasis on triple-negative breast cancer. The company aims to selectively inhibit specific pathways involved in disease progression without affecting physiological processes associated with chronic conditions such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. By utilizing disease-specific antibodies, Periotherapia contributes to early diagnosis and precision medicine, enhancing the ability of healthcare professionals to identify and create new therapeutic options for various challenging medical conditions.

PaMeLa Co., Ltd. is a medical device company based in Suita, Japan, founded in 2016. The company focuses on developing innovative technology to measure pain experienced by patients during surgical procedures. By utilizing brain wave analysis, algorithms, and machine learning, PaMeLa aims to create an objective method for quantifying pain. This approach is intended to enhance medical care by providing a scientific basis for pain assessment, thereby improving patient outcomes and treatment strategies.

ThinkCyte, Inc. is a biotechnology company that specializes in developing an artificial intelligence-enabled, image-free visual cell sorting system, which sorts cells based on their morphology. Founded in 2016 and headquartered in Tokyo, Japan, with an additional office in San Carlos, California, ThinkCyte utilizes advanced optics and machine learning to create its ghost cytometry technology. This innovative approach allows for ultra-high throughput and content-rich analysis of single cells, facilitating research, diagnostics, and therapeutics across various medical disciplines such as drug discovery and cell therapy. The company's cell sorting technology enables researchers to identify and isolate specific cells, including rare ones, in real-time, advancing the capabilities of single-cell analysis.

C4U Co., Ltd. is a life science start-up based in Suita, Japan, specializing in the research and development of advanced genome editing technologies. Founded in 2018, the company focuses on utilizing CRISPR and Cas3 methods to create innovative tools for drug discovery and therapeutic applications. C4U aims to address various intractable diseases and contribute to solutions for pressing social issues across multiple sectors, including medicine, agriculture, forestry, livestock, and fisheries. By developing a robust platform for gene editing, C4U supports pharmaceutical companies in their quest for new gene therapy methods and enhances the potential for groundbreaking advancements in healthcare and beyond.

SK Fine specializes in advanced ceramics manufacturing. It pioneered Japan's first commercial 3D printer for ceramics and offers custom 3D ceramic parts based on client-provided CAD data.

Founded in 2018, Aipore specializes in developing nanopore sensors using semiconductor Si microfabrication technology. These sensors measure and analyze changes in ion current flow, enabling accurate identification of particles such as viruses for diverse industrial applications like microbiological testing, cancer detection, and environmental evaluation.

COTOBADESIGN, Inc. specializes in the development and delivery of dialogue artificial intelligence (AI) content. Established in 2017 and headquartered in Tokyo, Japan, the company offers innovative tools aimed at enhancing productivity in various sectors, including elderly and nursing care, business automation, and entertainment. Additionally, COTOBADESIGN provides a platform that supports the development of dialogue AI content, catering to the growing demand for automated communication solutions across different markets.

AI Samurai Inc. is a Tokyo-based company founded in 2015 that focuses on the development and sale of artificial intelligence technology. The company specializes in creating a patent examination platform that utilizes AI to evaluate patentability and conduct comprehensive patent searches. This platform supports clients in analyzing patent documents, thereby facilitating research and development efforts. In addition to its core offerings, AI Samurai also engages in patent research and technical investigation, providing valuable insights and services to enhance innovation in the field of artificial intelligence. The company also maintains a branch office in Osaka, expanding its reach within Japan.

NanoMist Technologies engages with R&D, design, and sells machines in the areas such as alcoholic beverages and food enrichment, fragrance extraction, chemical purification process, wastewater management, and deodorization process. NanoMist Technologies manufactures and sells machines such as ultrasonic atomization machine, deodorization machine, hot spring water concentration machine, solvent recovery machine, VOCs recovery machine, and granular material production machine.

C4U Co., Ltd. is a life science start-up based in Suita, Japan, specializing in the research and development of advanced genome editing technologies. Founded in 2018, the company focuses on utilizing CRISPR and Cas3 methods to create innovative tools for drug discovery and therapeutic applications. C4U aims to address various intractable diseases and contribute to solutions for pressing social issues across multiple sectors, including medicine, agriculture, forestry, livestock, and fisheries. By developing a robust platform for gene editing, C4U supports pharmaceutical companies in their quest for new gene therapy methods and enhances the potential for groundbreaking advancements in healthcare and beyond.

MediTact is Contribute to the medical society through the challenging development of medical technologies that meet patient treatment needs.

ThinkCyte, Inc. is a biotechnology company that specializes in developing an artificial intelligence-enabled, image-free visual cell sorting system, which sorts cells based on their morphology. Founded in 2016 and headquartered in Tokyo, Japan, with an additional office in San Carlos, California, ThinkCyte utilizes advanced optics and machine learning to create its ghost cytometry technology. This innovative approach allows for ultra-high throughput and content-rich analysis of single cells, facilitating research, diagnostics, and therapeutics across various medical disciplines such as drug discovery and cell therapy. The company's cell sorting technology enables researchers to identify and isolate specific cells, including rare ones, in real-time, advancing the capabilities of single-cell analysis.

Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, established in 2005. The company specializes in developing artificial chromosome technologies, primarily focusing on applications within the life sciences sector. Chromocenter's innovative approach utilizes artificial chromosome vectors to facilitate drug discovery and the construction of stable gene expression cell lines, which are essential for high protein production. Additionally, the company offers services such as chromosome analysis and various forms of fluorescence in situ hybridization (FISH), including multicolor and monochrome analysis. Through its advanced technologies, Chromocenter aims to provide clinicians with safe and effective pharmaceuticals for treating a range of diseases.

Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, established in 2005. The company specializes in developing artificial chromosome technologies, primarily focusing on applications within the life sciences sector. Chromocenter's innovative approach utilizes artificial chromosome vectors to facilitate drug discovery and the construction of stable gene expression cell lines, which are essential for high protein production. Additionally, the company offers services such as chromosome analysis and various forms of fluorescence in situ hybridization (FISH), including multicolor and monochrome analysis. Through its advanced technologies, Chromocenter aims to provide clinicians with safe and effective pharmaceuticals for treating a range of diseases.

Jeplan, Inc. is a Japanese company specializing in recycling technologies and systems aimed at promoting sustainable practices. Founded in January 2007 and based in Tokyo, it develops innovative solutions that cater to diverse consumer needs. The company utilizes proprietary chemical recycling technology to transform waste materials, such as food packaging and plastic PET bottles, into recycled polyethylene terephthalate (r-PET) resin and Bis(2-Hydroxyethyl) terephthalate (r-BHET) resin. These recycled materials are then used in the manufacturing of various products, including PET bottles and textiles. In addition to its technological advancements, Jeplan is involved in promoting the recycling of used uniforms and offers consulting services to businesses looking to implement recycling initiatives. Through its efforts, Jeplan aims to enhance recycling efficiency and contribute to environmental sustainability.

GlyTech specializes in the production of human-type N-glycans and chemical glycosylation technologies. It offers custom synthesis services, contract manufacturing, and licenses its products for use in biopharmaceuticals and oligonucleotide therapeutics.

Immunosens develops electrochemical measurement devices that evaluate biomarkers such as genes, proteins, and cell signals through electrode reactions. Its sensors rely on disposable printable electrodes, enabling healthcare professionals to obtain accurate analyses for medical diagnostics and food safety testing. The platform aims to deliver rapid, on-site biomarker readouts and can be integrated into existing clinical workflows, offering a scalable solution for both clinical and food industry applications.

Founded in Japan in 2017, Luxna Biotech specializes in developing nucleic acid drugs using advanced artificial technology. The company focuses on creating safe and effective oligonucleotide therapeutics based on licensed cross-linked modified nucleic acid groups.

Pi-Crystal Incorporation, founded in 2013 and headquartered in Osaka, Japan, specializes in the development and manufacture of printable organic semiconductor integrated circuits. The company focuses on research and development, design, and sales of organic semiconductor materials and devices, utilizing innovative technologies that differ significantly from traditional silicon semiconductors. Its products are designed for flexibility and low-cost production, making them suitable for various industrial applications. By leveraging unique materials and film formation methods, Pi-Crystal enables clients to create soft, thin, lightweight, and inexpensive devices, contributing to advancements in the Internet of Things sector.

Periotherapia is a drug discovery company focused on developing medical treatments for intractable diseases, with a primary emphasis on triple-negative breast cancer. The company aims to selectively inhibit specific pathways involved in disease progression without affecting physiological processes associated with chronic conditions such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. By utilizing disease-specific antibodies, Periotherapia contributes to early diagnosis and precision medicine, enhancing the ability of healthcare professionals to identify and create new therapeutic options for various challenging medical conditions.

Elvez is a company focused on the research, development, and commercialization of dialogue technology. It provides a range of services, including a training management system, a WordPress plugin, and AI-based consulting services. Elvez aims to address social issues through its technology, offering solutions that are accessible via smartphones and web browsers. By leveraging AI technology, the company seeks to enhance the effectiveness of consulting services, particularly for seniors, thereby facilitating better engagement with technology.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

Founded in Japan in 2017, Remohab specializes in remote telemedicine solutions for rehabilitation patients. Its core product, the Remohub system, leverages IoT and ICT technologies to connect patients at home with medical institutions remotely, facilitating cardiac rehabilitation.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The company's innovative technology enables the extraction of detailed structural and functional information from immune cell sequences derived from routine blood samples. This capability has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with academic institutions and pharmaceutical companies to advance research and development, focusing on the creation of diagnostic and therapeutic methods. Their platform, known as Repertoire Builder, organizes immune receptors based on their target epitopes, utilizing sequence and structural features from B and T cell receptor models. This functionality helps delineate the functional landscape of individual donors and quantifies variations between different individuals, ultimately supporting drug discovery and improving diagnostic and prognostic capabilities.

KYSHOW Corporation, founded in 1994 and based in Osaka, Japan, operates seafood retail stores that specialize in high-quality fresh fish. The company focuses on domestically produced live natural fish sourced from Japan's coastal waters, ensuring freshness and quality for its customers. In addition to retailing fresh fish, KYSHOW also manufactures and distributes seasonal gifts, particularly midyear and year-end offerings, in collaboration with renowned department stores. This dual approach enables consumers to access fresh seafood while providing options for gift-giving, catering to both everyday and special occasion needs.

Bioworks Corporation, established in 2015 and headquartered in Tokyo, Japan, specializes in the modification and sale of polylactic acid and its derivatives. The company focuses on enhancing the properties of polylactic acid to create modified compounds that meet various industrial needs. As of December 2018, Bioworks operates as a subsidiary of TBM Co., Ltd. Through its innovative approaches in bioplastics, Bioworks aims to contribute to sustainable material solutions in the production industry.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The company's innovative technology enables the extraction of detailed structural and functional information from immune cell sequences derived from routine blood samples. This capability has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with academic institutions and pharmaceutical companies to advance research and development, focusing on the creation of diagnostic and therapeutic methods. Their platform, known as Repertoire Builder, organizes immune receptors based on their target epitopes, utilizing sequence and structural features from B and T cell receptor models. This functionality helps delineate the functional landscape of individual donors and quantifies variations between different individuals, ultimately supporting drug discovery and improving diagnostic and prognostic capabilities.

PGV Co., Ltd., founded in September 2016 and based in Japan, specializes in the development of electroencephalogram (EEG) related technologies. The company focuses on creating innovative brain wave sensor devices, specifically patch-type electroencephalographs, which allow for the accurate measurement of brain waves in a manner similar to using a thermometer. By integrating artificial intelligence for data analysis, PGV aims to facilitate self-care through the continuous monitoring of brain activity, thereby enhancing personal health management. The company's advancements are designed to support medical professionals in delivering efficient and effective patient care through accurate data collection and machine learning applications.

KOTAI Biotechnologies, Inc. is a biotechnology company based in Osaka, Japan, specializing in the development of a structural modeling and analysis platform for immune cell receptors. The company's innovative technology enables the extraction of detailed structural and functional information from immune cell sequences derived from routine blood samples. This capability has significant implications for understanding resistance to infections, autoimmune diseases, and cancer. KOTAI collaborates with academic institutions and pharmaceutical companies to advance research and development, focusing on the creation of diagnostic and therapeutic methods. Their platform, known as Repertoire Builder, organizes immune receptors based on their target epitopes, utilizing sequence and structural features from B and T cell receptor models. This functionality helps delineate the functional landscape of individual donors and quantifies variations between different individuals, ultimately supporting drug discovery and improving diagnostic and prognostic capabilities.

Chromocenter Inc. is a biopharmaceutical company based in Yonago, Japan, established in 2005. The company specializes in developing artificial chromosome technologies, primarily focusing on applications within the life sciences sector. Chromocenter's innovative approach utilizes artificial chromosome vectors to facilitate drug discovery and the construction of stable gene expression cell lines, which are essential for high protein production. Additionally, the company offers services such as chromosome analysis and various forms of fluorescence in situ hybridization (FISH), including multicolor and monochrome analysis. Through its advanced technologies, Chromocenter aims to provide clinicians with safe and effective pharmaceuticals for treating a range of diseases.

Kyoto Drug Discovery and Development Co. Ltd., based in Kyoto, Japan, specializes in the development of innovative therapeutic drugs targeting chronic degenerative eye diseases. The company focuses on creating effective treatments for conditions such as glaucoma, central retinal artery occlusion, retinal pigmentosa, and age-related macular degeneration. By addressing these intractable eye diseases, Kyoto Drug Discovery and Development aims to provide healthcare professionals with advanced options to improve patient outcomes and manage debilitating ocular conditions.

AFI Technology is a Seoul-based developer and manufacturer of inspection and monitoring technology for science, engineering, medicine, and the environment. The company offers electric filter separation technology and rapid detection systems for microbial contamination risk monitoring, and provides products designed for rapid microbiological testing and environment-oriented solutions.

FunPep specializes in the research and development of pharmaceutical products, cosmetics, and medical devices utilizing functional peptides. Its primary focus is on creating innovative treatments for intractable ulcers and exploring next-generation pharmaceutical alternatives to antibody medicines.

Matrixome Inc is a scientific research company based in Osaka, Japan, dedicated to the research and development of protein-based pharmaceutical preparations. Incorporated in 2015, the company focuses on the study of matrixosomes, a concept introduced by Professor Kiyotoshi Sekiguchi, which emphasizes the interactions between cells and their extracellular environment. Matrixome's product offerings include iMAtrix-221, a substrate designed for the purification and maintenance of cardiomyocytes; iMatrix-441, which induces endothelial progenitor cells for induced pluripotent stem cells; and iMatrix-511, a recombinant human laminin-511 E8 fragment intended for use in cell culture. Through its innovative research, Matrixome aims to provide valuable insights for biotechnology researchers and advance the field of regenerative medicine.

Founded in 1993, JTEC specializes in designing, manufacturing, and selling X-ray mirrors for synchrotron facilities, enabling research across various fields. The company also develops automated cell culture systems and other automated solutions.

Microwave Chemical develops and provides microwave chemistry solutions and services across research, development, and engineering. It leverages a microwave chemistry platform designed to match product characteristics, enabling rapid experimentation, process optimization, and scalable implementation for diverse chemical applications.